GE HealthCare Q2 Beats Across the Board, Reaffirms 2026 Outlook
GEHC sits 15% above its 52-week low of $58.75.
Summary
GE HealthCare delivered a clean Q2 beat: revenue of $5.30B edged past the $5.26B consensus, and adjusted EPS of $1.13 handily topped the $1.04 estimate. Net income hit $561M, or $1.24 per share. Growth was fueled by Pharmaceutical Diagnostics and Advanced Imaging Solutions, while Patient Care Solutions remained a drag. The company also bought back $200M in stock during the quarter. Management reaffirmed full-year 2026 guidance for 3-4% organic revenue growth, adjusted EPS of $4.80-$5.00, and free cash flow of about $1.6B. This follows the preliminary Q2 numbers and CFO departure announced last week — the full release confirms the strength and adds the buyback and segment color. Tariff refunds provided a tailwind, but inflation in memory chips, oil, and freight is pressuring margins. With shares trading at 12x forward earnings, well below the three-month-ago multiple of 14x, the beat and steady outlook could support the recent rebound from the post-CFO-drop selloff.
Updates
· Dow Jones Newswires — Q2 orders rose 11%, and management issued Q3 guidance for 3-4% organic revenue growth and low-double-digit adjusted EPS growth. Shares jumped 12%, on pace for a record daily gain.
At the time of this announcement, GEHC was trading at $67.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.2B. The 52-week trading range was $58.75 to $89.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.